MicroGenDX Press Releases

Disruptive new multicenter research has determined that next generation sequencing (NGS) can reliably predict treatment failure due to periprosthetic joint infection (PJI). MicroGenDX, the High Complexity Laboratory utilized in the study, is upending outdated approaches to infection detection, instead relying on the most up-to-date technologies to not only determine that an infection is present, but to identify the exact micro-organism(s) involved.

MicroGenDX, a high complexity lab based out of Florida, is not under investigation by the FDA and is, and always has been, in good standing with the College of American Pathologists. The purpose of this post is to address concerns arising from false and inaccurate information that is contained within an article titled FDA investigates lab as tens of thousands of COVID-19 test results in Florida are questioned, published on May 21, 2020 and updated on July 22, 2020 by USAToday.com and other websites. This article has been promoted through social media by competitors of MicroGenDX, and others with agendas […]

MicroGenDX, the world leader in providing Next Generation DNA Sequencing (NGS) in microbial identification, processed samples in the groundbreaking study “Next Generation Sequencing for the Diagnosis of Periprosthetic Knee Infection: A Multicenter Investigation” led by the Rothman Institute. The study recently accepted the Eastern Orthopaedic Association’s Musculoskeletal Infection Award and further evidenced that advanced molecular diagnostic testing gives hope to patients suffering from devastating chronic infections.

MicroGenDX Laboratories equipped a multicenter study with its gold standard NGS test to investigate the persistence of Periprosthetic Joint Infection (PJI). Renowned orthopedic surgeon Javad Parvizi, MD will take the podium at American Association of Hip and Knee Surgeons (AAHKS) to discuss results of the study to show how NGS is revolutionizing the microbial diagnosis of chronic infections in orthopedics.